Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
NCT04704869 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
Conditions Studied
Interventions
- BIOLOGICAL Cryoprecipitate
- BIOLOGICAL Red Blood Cells
- BIOLOGICAL Plasma
- BIOLOGICAL Platelets
- BIOLOGICAL Whole Blood
Study Locations (20)
Other
- Queen Elizabeth Hospital — Birmingham
- Royal Sussex County Hospital — Brighton
- Southmead Hospital — Bristol
- Addenbrooke's Hospital — Cambridge
- University Hospital of Wales — Cardiff
- University Hospital of Coventry and Warwickshire — Coventry
- Hull Royal Infirmary — Hull
- Leeds General Infirmary — Leeds
- University Hospital Aintree — Liverpool
- Royal London Hospital — London
- King's College Hospital — London
- St. George's Hospital — London
- St. Mary's Hospital — London
- Manchester Royal Infirmary — Manchester
- Salford Royal Hospital — Manchester
- James Cook University Hospital — Middlesbrough
- Royal Victoria Infirmary — Newcastle upon Tyne
- Queens Medical Centre — Nottingham
- John Radcliffe Hospital — Oxford
Texas
- The University of Texas Health Science Center at Houston — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,604 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04704869
The ClinicalTrials.gov registry entry for NCT04704869 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bryan Cotton, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Trauma Injury appearing as the primary indexed condition, and to 5 interventions — of which Cryoprecipitate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04704869 reports 20 study locations spanning 2 distinct geographic areas — top geographies include Other, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04704869 about?
NCT04704869 is a clinical study titled "Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation". The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
What is the current status of trial NCT04704869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,604 participants. The study started on 2017-01. Estimated completion is 2022-11-01.
What conditions does trial NCT04704869 study?
This clinical trial studies the following conditions: Trauma Injury. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04704869?
The interventions under investigation include: Cryoprecipitate (BIOLOGICAL), Red Blood Cells (BIOLOGICAL), Plasma (BIOLOGICAL), Platelets (BIOLOGICAL), Whole Blood (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04704869?
This trial is sponsored by Bryan Cotton, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04704869 being conducted?
This trial has 20 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.